Investors Face Losses in Zoetis Securities Class Action

The complaint centers on claims that Zoetis downplayed significant headwinds facing its core veterinary portfolio. According to the filing, the company failed to disclose that demand for the canine pain treatment Librela faltered after FDA safety warnings highlighted potential neurological complications in dogs. Simultaneously, the firm’s parasiticide, Simparica Trio, reportedly surrendered market share to lower-priced competitors as the broader market slowed.

Further allegations suggest that Zoetis’ dermatology mainstays, Apoquel and Cytopoint, also lost ground to newly introduced rivals. Investors who purchased ZTS stock during the specified window are encouraged to register their information with The Gross Law Firm. Participation in the action does not require appointment as a lead plaintiff, and the firm notes that registrants will be enrolled in portfolio monitoring to track the litigation’s progress.